Table 4.
The characteristics and differences of the NSD-ISS and the SynNeurGe research criteria
| NSD-ISS | SynNeurGe | |
|---|---|---|
| Purpose | Biological definition of disease | Biological definition of disease |
| Classification system | Yes | Yes |
| Integrated staging system | Yes | No |
| Disease Label | Neuronal α-synuclein disease | Parkinson’s disease |
| Genetic variants considered | Yes | Yes |
| α-Synuclein pathology | Yes | Yes |
| CSF seed amplification assays | Yes | Yes |
| Other assays involved | No | Skin seed amplification assays, skin immunohistochemistry |
| Neuronal dysfunction/neurodegeneration | Yes | Yes |
| DAT scan | Yes | Yes |
| Other imaging modalities | No | [18F]fluorodeoxyglucose-PET, metaiodobenzylguanidine SPECT |
| Staging system | Yes | No |
| Clinical signs and symptoms usage | Not used for diagnosis; used to distinguish stages | Not used for diagnosis; provides a list of related signs and symptoms |
DAT, Dopamine transporter; SPECT, single-photon emission computed tomography